Shoker Investment Counsel Inc. Purchases 5,673 Shares of iShares NASDAQ Biotechnology Index (IBB)

Shoker Investment Counsel Inc. grew its position in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 202.0% in the 4th quarter, HoldingsChannel reports. The fund owned 8,481 shares of the financial services provider’s stock after buying an additional 5,673 shares during the period. Shoker Investment Counsel Inc.’s holdings in iShares NASDAQ Biotechnology Index were worth $905,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Folger Nolan Fleming Douglas Capital Management Inc. grew its holdings in iShares NASDAQ Biotechnology Index by 208.2% during the fourth quarter. Folger Nolan Fleming Douglas Capital Management Inc. now owns 43,957 shares of the financial services provider’s stock worth $4,693,000 after buying an additional 29,693 shares in the last quarter. Global Endowment Management LP grew its holdings in iShares NASDAQ Biotechnology Index by 200.0% during the fourth quarter. Global Endowment Management LP now owns 4,500 shares of the financial services provider’s stock worth $480,000 after buying an additional 3,000 shares in the last quarter. YorkBridge Wealth Partners LLC grew its holdings in iShares NASDAQ Biotechnology Index by 197.1% during the fourth quarter. YorkBridge Wealth Partners LLC now owns 1,628 shares of the financial services provider’s stock worth $174,000 after buying an additional 1,080 shares in the last quarter. Navellier & Associates Inc bought a new stake in iShares NASDAQ Biotechnology Index during the fourth quarter worth $721,000. Finally, Madison Investment Holdings Inc. bought a new stake in iShares NASDAQ Biotechnology Index during the fourth quarter worth $320,000. Hedge funds and other institutional investors own 38.31% of the company’s stock.

Shares of iShares NASDAQ Biotechnology Index (NASDAQ IBB) opened at $108.42 on Friday. iShares NASDAQ Biotechnology Index has a 1-year low of $94.20 and a 1-year high of $119.30. The stock has a market capitalization of $9,510.00, a price-to-earnings ratio of 3.58 and a beta of 1.37.

ILLEGAL ACTIVITY NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/23/shoker-investment-counsel-inc-purchases-5673-shares-of-ishares-nasdaq-biotechnology-index-ibb.html.

iShares NASDAQ Biotechnology Index Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply